Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 241500
Corporate User License Price USD 4500
Corporate User License Price INR 310500
Site License Price USD 4000
Site License Price INR 276000
Request a Quote

Report Title

Global Respiratory Drugs Pipeline Analysis Market 2018

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 4000
Enterprise Wide License USD 4500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Global Respiratory Drugs Pipeline Analysis Market 2018


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Global Respiratory Drugs Pipeline Analysis Market 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Global Respiratory Drugs Pipeline Analysis Market 2018



Executive Summary

Respiratory Drugs Pipeline Analysis

Overview: Pulmonary medicine is the branch of medical science that deals with diagnosis, prevention, and treatment of diseases affecting the respiratory system. Respiratory drugs finds its applications in Asthma, COPD, Cystic Fibrosis, Allergic Rhinitis and Others. Asthma is the major market share holder currently. The intensity of competition in the respiratory drug market is high with few players dominating the market. The high investments made in the development of respiratory drug delivery systems have favored the growth of the market. The entry of innovative and effective drugs in the market is expected to drive the future of the market.

Short-Acting Beta2-Agonists (SABA), Inhaled corticosteroids (ICS), anticholinergics, long-acting beta2-agonists (LABA), antihistamines, vasodilators, combination drugs, and others are the major respiratory dugs classes available in the market. Currently, primarily combination drugs drive the market, with top brands facing no real competition from generic alternatives. The emergence of inexpensive, state-of-the-art and effective drug delivery devices will provide stimulate the market growth.

Industry Trends

GSK's Adavir for Asthma and COPD remains as the top selling drug in the market, even on declined revenue in 2017

Pharmaceutical companies in US are facing pricing pressure and launch of new respiratory drugs in the market are declining the sales of the blockbuster drugs in the market

Cipla Ltd., a leader in the Indian market, announced in May 2017, that it planned to reduce the investment on the biosimilars, to increase their focus on the respiratory drugs due to the high profitability

More than 30 companies pipeline for the respiratory drugs is analyzed in the study. GlaxoSmithKline plc has the highest number of pipeline molecules in various clinical trials phases.

Benefits: The report provides complete details about the usage and adoption rate of respiratory drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

 

Table of Contents

1 Industry Outlook 12

1.1 Industry Overview 12

1.1.1 Global Driver for Pharmaceutical Demand: 13

1.1.2 Pharmaceutical spending region wise 13

1.1.3 R&D pipeline in pharmaceutical industry 13

1.1.4 Top pharma drugs by sales in 2017 (USD Million) 15

1.2 Industry Trends 17

1.3 Pest Analysis 17

2 Report Outline 19

2.1 Report Scope 19

2.2 Report Summary 19

2.3 Research Methodology 19

2.4 Report Assumptions 20

3 Market Snapshot 21

3.1 Market Definition-Infoholic Research 21

3.2 Segment Addressable Market 21

3.1 Trends of Respiratory Drugs Market 21

4 Molecule Type: Analysis 23

4.1 Overview 23

5 Application: Analysis 25

5.1 Overview 25

5.2 Asthma 25

5.2.1 Key Takeaways 30

5.2.2 Company Analysis 31

5.3 Chronic Obstructive Pulmonary Disease (COPD) 31

5.3.1 Key Takeaways 35

5.3.2 Company Analysis 36

5.4 Cystic Fibrosis 36

5.4.1 Key Takeaways 40

5.4.2 Company Analysis 40

5.5 Lung Cancer 40

5.5.1 Key Takeaways 45

5.5.2 Company Analysis 46

5.6 Nasal Polyps 46

5.6.1 Key Takeaways 47

5.7 Idiopathic Pulmonary Fibrosis 48

5.7.1 Key Takeaways 50

5.7.2 Company Analysis 50

5.8 Others 51

6 Competitive Landscape 52

6.1.1 Company Analysis 53

7 Vendors Profile 55

7.1 AbbVie Inc. 55

7.1.1 Overview 55

7.1.2 Geographic Presence 58

7.1.3 Business Focus 58

7.1.4 SWOT Analysis 59

7.1.5 Business Strategies 59

7.2 Amgen Inc. 60

7.2.1 Overview 60

7.2.2 Geographic Presence 63

7.2.3 Business Focus 64

7.2.4 SWOT Analysis 65

7.2.5 Business Strategies 67

7.3 Astra Zeneca PLC 67

7.3.1 Overview 67

7.3.2 Geographic Presence 71

7.3.3 Business Focus 71

7.3.4 SWOT Analysis 72

7.3.5 Business Strategy 72

7.4 Bayer AG 73

7.4.1 Overview 73

7.4.2 Business Unit 74

7.4.3 Geographic Presence 75

7.4.4 Business Focus 76

7.4.5 SWOT Analysis 76

7.4.6 Business Strategy 77

7.5 Boehringer Ingelheim GmbH 77

7.5.1 Overview 77

7.5.2 Geographic Presence 81

7.5.3 Business Focus 81

7.5.4 SWOT Analysis 81

7.5.5 Business Strategy 82

7.6 Bristol-Myers Squibb 83

7.6.1 Overview 83

7.6.2 Geographic Presence 87

7.6.3 Business Focus 87

7.6.4 SWOT Analysis 87

7.6.5 Business Strategy 88

7.7 Celgene Corporation 89

7.7.1 Overview 89

7.7.2 Geographic Presence 90

7.7.3 Business Focus 91

7.7.4 SWOT Analysis 91

7.7.5 Business Strategy 92

7.8 Dr. Reddy's Laboratories Limited 93

7.8.1 Overview 93

7.8.2 Business Unit 97

7.8.3 Geographic Presence 99

7.8.4 Business Focus 99

7.8.5 SWOT Analysis 100

7.8.6 Business Strategy 100

7.9 Eli Lilly & Company Ltd 101

7.9.1 Overview 101

7.9.2 Business Focus 103

7.9.3 SWOT Analysis 104

7.9.4 Business Strategies 104

7.10 F.Hoffmann-La Roche Ltd. 105

7.10.1 Overview 105

7.10.2 Business Unit 108

7.10.3 Geographic Presence 109

7.10.4 Business Focus 109

7.10.5 SWOT Analysis 110

7.10.6 Business Strategy 110

7.11 GlaxoSmithKline plc 111

7.11.1 Overview 111

7.11.2 Geographic Presence 115

7.11.3 Business Focus 115

7.11.4 SWOT Analysis 116

7.11.5 Business Strategy 116

7.12 Johnson & Johnson 117

7.12.1 Overview 117

7.12.2 Business Units 120

7.12.3 Geographic Revenue 121

7.12.4 Business Focus 122

7.12.5 SWOT Analysis 123

7.12.6 Business Strategies 123

7.13 Merck & Co., Inc. 124

7.13.1 Overview 124

7.13.2 Business units 126

7.13.3 Geographic Revenue 127

7.13.4 Business focus 128

7.13.5 SWOT analysis 128

7.13.6 Business strategies 129

7.14 Mylan N.V. 129

7.14.1 Overview 129

7.14.2 Geographic Presence 133

7.14.3 Business Focus 133

7.14.4 SWOT Analysis 134

7.14.5 Business Strategy 134

7.15 Novartis AG 134

7.15.1 Overview 134

7.15.2 Business Unit 136

7.15.3 Geographic Presence 137

7.15.4 Business Focus 138

7.15.5 SWOT Analysis 138

7.15.6 Business Strategy 139

7.16 Pfizer, Inc., 140

7.16.1 Overview 140

7.16.2 Business Units 143

7.16.3 Geographic Presence 143

7.16.4 Business Focus 144

7.16.5 SWOT Analysis 144

7.16.6 Business Strategies 144

7.17 Sanofi 145

7.17.1 Overview 145

7.17.2 Geographic Presence 148

7.17.3 Business Focus 148

7.17.4 SWOT Analysis 148

7.17.5 Business Strategy 149

7.18 Teva Pharmaceutical Industries Ltd. 149

7.18.1 Overview 149

7.18.2 Business Unit 152

7.18.3 Geographic Presence 152

7.18.4 Business focus 153

7.18.5 SWOT analysis 153

7.18.6 Business Strategy 154

7.19 Vertex Pharmaceuticals Inc. 155

7.19.1 Overview 155

7.19.2 Geographic Presence 158

7.19.3 Business Focus 158

7.19.4 SWOT Analysis 159

7.19.5 Business Strategy 159

8 Companies to Watch For 160

8.1 FibroGen, Inc 160

8.1.1 Overview 160

8.1.2 Highlights 160

8.2 Gilead Sciences Inc. 161

8.2.1 Overview 161

8.2.2 Highlights: 162

8.3 Glenmark Pharmaceutical Ltd 163

8.3.1 Overview 163

8.4 Zia Labs 164

8.4.1 Overview 164

8.4.2 Zia Lab: Highlights 164

8.5 Vectura Group Plc 165

8.5.1 Overview 165

8.5.2 Vectura Group Plc: Highlights 166

8.6 Sosei Group Corporation 166

8.6.1 Overview 166

8.7 Almirall S.A. 167

8.7.1 Overview 167

8.8 Biogen Inc 168

8.8.1 Overview 168

8.9 CHIESI Farmaceutici SpA 169

8.9.1 Overview 169

8.9.2 CHIESI Farmaceutici SpA: Highlights 170

8.10 Takeda Pharmaceutical Co, Ltd 170

8.10.1 Overview 170

8.10.2 Highlights 171

8.11 Shionogi & Co., Ltd 171

8.11.1 Overview 171

8.11.2 Shionogi & Co., Ltd: Highlights 172

8.12 Sun Pharmaceuticals 172

8.12.1 Overview 172

8.12.2 Highlights 173

8.13 United Therapeutics Corp 173

8.13.1 Overview 173

8.13.2 Highlights 174

8.14 ProMetic Life Sciences Inc. 174

8.14.1 Overview 174

8.14.2 ProMetic Life Sciences Inc.: Highlights 175

8.15 Daiichi Sankyo, Inc. 175

8.15.1 Overview 175

8.15.2 Overview 176

8.16 Aurobindo Pharma Ltd 176

8.16.1 Overview 176

8.16.2 Aurobindo Pharma Ltd: Highlights 177

8.17 Eisai Co., Ltd 177

8.17.1 Overview 177

8.17.2 Eisai Co., Ltd: Highlights 178

8.18 Shire Plc 179

8.18.1 Overview 179

8.18.2 Shire Plc: Highlights 181

8.19 GNI Group Ltd 181

8.19.1 Overview 181

8.20 MediciNova, Inc 182

8.20.1 Overview 182

8.21 Ono Pharmaceutical Co., Ltd 182

8.21.1 Overview 182

8.22 Promedior, Inc 183

8.22.1 Overview 183

8.23 Sumitomo Dainippon Pharma Co., Ltd. 184

8.23.1 Overview 184

8.23.2 Sumitomo Dainippon Pharma Co., Ltd: Highlights 185

9 Annexure 186

Abbreviations 186

 

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

Charts

 

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 16

CHART 2 PHARMACEUTICAL MOLECULLES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS) 17

CHART 3 R&D INVESTMENT BY TOP 10 COMPANIES (USD BN) 18

CHART 4 PHARMACEUTICAL DRUGS BY SALES, 2017 19

CHART 5 PEST ANALYSIS OF RESPIRATORY DRUGS MARKET 20

CHART 6 RESEARCH METHODOLOGY OF RESPIRATORY DRUGS PIPELINE 22

CHART 7 NUMBER OF LARGE MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS 26

CHART 8 NUMBER OF SMALL MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS 26

CHART 9 RESPIRATORY PRODUCT PIPELINE BASED ON THE MOLECULE TYPE 27

CHART 1 RESPIRATORY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 VS 2024 (%) 28

CHART 2 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR ASTHMA 33

CHART 3 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 37

CHART 4 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 42

CHART 5 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR LUNG CANCER 48

CHART 6 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR LUNG CANCER 50

CHART 7 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR IDOPATHIC PULMONARY FIBROSIS 52

CHART 8 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR OTHER RESPIRATORY DISEASES 54

CHART 9 ABBVIEE INC: OVERVIEW SNAPSHOT 60

CHART 10 ABBVIEE INC.: GEOGRAPHIC PRESENCE 61

CHART 11 ABBVIE INC.: SWOT ANALYSIS 62

CHART 12 AMGEN INC.: OVERVIEW SNAPSHOT 65

CHART 13 AMGEN INC.: GEOGRAPHIC PRESENCE 66

CHART 14 AMGEN: SWOT ANALYSIS 68

CHART 15 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT 71

CHART 16 ASTRA ZENCA PLC: BUSINESS UNITS 73

CHART 17 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE 74

CHART 18 ASTRA ZENCA PLC: SWOT ANALYSIS 75

CHART 19 BAYER AG: OVERVIEW SNAPSHOT 77

CHART 20 BAYER AG: BUSINESS UNITS 77

CHART 21 BAYER GA: GEOGRAPHICAL PRESENCE 78

CHART 22 BAYER AG: SWOT ANALYSIS 79

CHART 23 BOEHRINGER INGELHEIM GMBH: OVERVIEW SNAPSHOT 81

CHART 24 BOEHRINGER INGELHEIM GMBH: BUSINESS UNITS 82

CHART 25 BOEHRINGER INGELHEIM GMBH: GEOGRAPHIC PRESENCE 84

CHART 26 BOEHRINGER INGELHEIM GMBH: SWOT ANALYSIS 84

CHART 27 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT 88

CHART 28 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS 89

CHART 29 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE 90

CHART 30 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS 90

CHART 31 CELGENE CORPORATION: OVERVIEW SNAPSHOT 93

CHART 32 CELGENE CORPORATION: GEOGRAPHIC PRESENCE 93

CHART 33 CELGENE CORPORATION: SWOT ANALYSIS 94

CHART 34 DR. REDDY'S LABORATORY LIMITED: OVERVIEW SNAPSHOT 100

CHART 35 DR. REDDY'S LABORATORY LIMITED: BUSINESS UNITS 100

CHART 36 DR. REDDY'S LABORATORY LIMITED: GEOGRAPHICAL PRESENCE 102

CHART 37 DR. REDDY'S LABORATORY LIMITED: SWOT ANALYSIS 103

CHART 38 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 105

CHART 39 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 105

CHART 40 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE 106

CHART 41 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS 107

CHART 42 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 108

CHART 43 F. HOFFMANN.LA ROCHE LTD.: BUSINESS UNITS 111

CHART 44 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE 112

CHART 45 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 113

CHART 46 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 114

CHART 47 GLAXOSMITHKLINE PLC: BUSINESS UNITS 117

CHART 48 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE 118

CHART 49 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 119

CHART 50 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 122

CHART 51 JOHNSON & JOHNSON: BUSINESS UNITS 123

CHART 52 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 124

CHART 53 JOHNSON & JOHNSON: SWOT ANALYSIS 126

CHART 54 MERCK & CO: OVERVIEW SNAPSHOT 128

CHART 55 MERCK & CO: BUSINESS UNITS 129

CHART 56 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 130

CHART 57 MERCK & CO: SWOT ANALYSIS 131

CHART 58 MYLAN N.V. OVERVIEW SNAPSHOT 134

CHART 59 MYLAN N.V..: BUSINESS SEGMENTS 134

CHART 60 MYLAN N.V..: GEOGRAPHIC PRESENCE 136

CHART 61 MYLAN N.V..: SWOT ANALYSIS 137

CHART 62 NOVARTIS AG: OVERVIEW SNAPSHOT 139

CHART 63 NOVARTIS AG: BUSINESS UNITS 139

CHART 64 NOVARTIS AG: GEOGRAPHICAL PRESENCE 140

CHART 65 NOVARTIS AG: SWOT ANALYSIS 141

CHART 66 PFIZER, INC.: OVERVIEW SNAPSHOT 145

CHART 67 PFIZER INC.: BUSINESS UNITS 146

CHART 68 PFIZER INC.: GEOGRAPHIC PRESENCE 146

CHART 69 PFIZER INC: SWOT ANALYSIS 147

CHART 70 SANOFI SA: OVERVIEW SNAPSHOT 149

CHART 71 SANOFI SA: SEGMENTATION 150

CHART 72 SANOFI SA: GEOGRAPHIC REVENUE 151

CHART 73 SANOFI SA: SWOT ANALYSIS 151

CHART 74 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT 154

CHART 75 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS 155

CHART 76 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL PRESENCE 155

CHART 77 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 156

CHART 78 VERTEX PHARMACEUTICALS INC.: OVERVIEW SNAPSHOT 160

CHART 79 VERTEX PHARMACEUTICALS INC.: GEOGRAPHICAL PRESENCE 161

CHART 80 VERTEX PHARMACEUTICALS INC.: SWOT ANALYSIS 162

 

Tables

 

TABLE 1 MOLECULES IN PIPELINE FOR ASTHMA 27

TABLE 2 MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 33

TABLE 3 MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 37

TABLE 4 MOLECULES IN PIPELINE FOR LUNG CANCER 42

TABLE 5 MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS 47

TABLE 6 MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS 49

TABLE 7 ABBVIE INC.: OFFERINGS 56

TABLE 8 ABBVIE INC: RECENT DEVELOPMENTS 56

TABLE 9 AMGEN INC.: OFFERINGS 61

TABLE 10 AMGEN INC.: RECENT DEVELOPMENTS 61

TABLE 11 ASTRA ZENCA PLC: OFFERINGS 68

TABLE 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS 69

TABLE 13 BAYER AG: OFFERINGS 74

TABLE 14 BAYER AG: RECENT DEVELOPMENTS 74

TABLE 15 BOEHRINGER INGELHEIM GMBH: OFFERINGS 79

TABLE 16 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 79

TABLE 17 BRISTOL-MYERS SQUIBB: OFFERINGS 84

TABLE 18 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT 84

TABLE 19 CELGENE CORPORATION: OFFERINGS 90

TABLE 20 CELGENE CORPORATION: RECENT DEVELOPMENTS 90

TABLE 21 DR. REDDY'S LABORATORIES LIMITED: PRODUCT OFFERINGS 94

TABLE 22 DR. REDDY'S LABORATORIES LIMITED: RECENT DEVELOPMENTS 94

TABLE 23 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 102

TABLE 24 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 102

TABLE 25 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS 106

TABLE 26 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 107

TABLE 27 GLAXOSMITHKLINE PLC: OFFERINGS 112

TABLE 28 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 113

TABLE 29 JOHNSON & JOHNSON: PRODUCT OFFERINGS 118

TABLE 30 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 118

TABLE 31 MERCK & CO: PRODUCT OFFERINGS 125

TABLE 32 MERCK & CO: RECENT DEVELOPMENTS 125

TABLE 33 MYLAN N.V.: OFFERINGS 131

TABLE 34 MYLAN N.V.: RECENT DEVELOPMENT 131

TABLE 35 NOVARTIS AG: OFFERINGS 136

TABLE 36 NOVARTIS AG: RECENT DEVELOPMENTS 136

TABLE 37 PFIZER, INC.: OFFERINGS 141

TABLE 38 PFIZER, INC.: RECENT DEVELOPMENTS 142

TABLE 39 SANOFI: OFFERINGS 146

TABLE 40 SANOFI: RECENT DEVELOPMENTS 146

TABLE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS 151

TABLE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS 151

TABLE 43 VERTEX PHARMACEUTICALS INC.: OFFERINGS 156

TABLE 44 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS 156

TABLE 45 FIBROGEN, INC: OVERVIEW 161

TABLE 46 FIBROGEN INC: RECENT DEVELOPMENTS 161

TABLE 47 GILEAD SCIENCES INC.: OVERVIEW 162

TABLE 48 GILEAD SCIENCE INC: RECENT DEVELOPMENTS 162

TABLE 49 GLENMARK PHARMACEUTICAL LTD: OVERVIEW 164

TABLE 50 GLENMARK PHARMACEUTICAL LTD: RECENT DEVELOPMENTS 164

TABLE 51 ZIA LAB: OVERVIEW 165

TABLE 52 ZIA LAB: RECENT DEVELOPMENTS 165

TABLE 53 VECTURA GROUP PLC: OVERVIEW 166

TABLE 54 VECTURA GROUP AG: RECENT DEVELOPMENTS 166

TABLE 55 SOSEI GROUP CORPORATION: OVERVIEW 167

TABLE 56 SOSEI GROUP CORPORATION: RECENT DEVELOPMENTS 167

TABLE 57 ALMIRALL S.A: OVERVIEW 168

TABLE 58 ALMIRALL S.A.: RECENT DEVELOPMENTS 169

TABLE 59 BIOGEN INC: OVERVIEW 169

TABLE 60 BIOGEN INC: RECENT DEVELOPMENTS 170

TABLE 61 CHIESI FARMACEUTICI SPA: OVERVIEW 170

TABLE 62 CHIESI FARMACEUTICI SPA: RECENT DEVELOPMENTS 170

TABLE 63 TAKEDA PHARMACEUTICAL CO, LTD.: OVERVIEW 171

TABLE 64 TAKEDA PHARMACEUTICAL CO, LTD: RECENT DEVELOPMENTS 171

TABLE 65 SHIONOGI & CO., LTD: OVERVIEW 172

TABLE 66 SHIONOGI & CO., LTD: RECENT DEVELOPMENTS 172

TABLE 67 SUN PHARMACEUTICALS: OVERVIEW 173

TABLE 68 ZIA LAB: RECENT DEVELOPMENTS 174

TABLE 69 UNITED THERAPEUTICS CORP.: OVERVIEW 174

TABLE 70 PROMETIC LIFE SCIENCES INC.: OVERVIEW 175

TABLE 71 PROMETIC LIFE SCIENCES INC.: RECENT DEVELOPMENTS 176

TABLE 72 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 176

TABLE 73 AUROBINDO PHARMA LTD: OVERVIEW 177

TABLE 74 AUROBINDO PHARMA LTD: RECENT DEVELOPMENTS 177

TABLE 75 EISAI CO., LTD: OVERVIEW 179

TABLE 76 EISAI CO., LTD: RECENT DEVELOPMENTS 179

TABLE 77 SHIRE PLC: OVERVIEW 180

TABLE 78 SHIRE PLC: RECENT DEVELOPMENTS 180

TABLE 79 GNI GROUP LTD: OVERVIEW 182

TABLE 80 GNI GROUP LTD: RECENT DEVELOPMENTS 182

TABLE 81 MEDICINOVA INC: OVERVIEW 183

TABLE 82 MEDICINOVA INC: RECENT DEVELOPMENTS 183

TABLE 83 ONO PHARMACEUTICAL CO., LTD: OVERVIEW 184

TABLE 84 ONO PHARMACEUTICAL CO., LTD: RECENT DEVELOPMENTS 184

TABLE 85 PROMEDIOR, INC: OVERVIEW 185

TABLE 86 PROMEDIOR INC: RECENT DEVELOPMENTS 185

TABLE 87 SUMITOMO DAINIPPON PHARMA CO., LTD: OVERVIEW 186

TABLE 88 SUMITOMO DAINIPPON PHARMA CO., LTD: RECENT DEVELOPMENTS 186

 

 

AbbVie Inc.Amgen Inc.Astra Zeneca PLCBayer Dr. Reddy's Laboratories Limited Eli Lilly & Company LtdF.Hoffmann-La Roche Ltd.GlaxoSmithKline plcMerck & Co., Inc.Mylan N.V. AG,Boehringer Ingelheim GmbH


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person